Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE0006632003
Mon, 11.10.2021
MorphoSys AG
Media Release
Planegg/Munich, Germany, October 11, 2021
MorphoSys' Licensing Partner Roche Received Breakthrough Therapy Designation for Gantenerumab in Alzheimer's Disease
MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that its licensing partner Roche (SIX: RO, ROG; OTCQX: RHHBY) received Breakthrough Therapy Designation by the U.S. Food [ … ]
Thu, 26.08.2021
MorphoSys AG
MorphoSys and Incyte Announce the European Commission Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
-The decision by the European Commission is based on data from the L-MIND study evaluating tafasitamab in combination with lenalidomide [ … ]
Tue, 24.08.2021
MorphoSys AG
Health Canada Grants Marketing Authorization for Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Minjuvi is a new therapeutic option for eligible patients with DLBCL in Canada to address an urgent unmet medical need
PLANEGG/Munich, Germany, - August [ … ]
Tue, 17.08.2021
MorphoSys AG
Media ReleaseMorphoSys' Partner Incyte Announced Development and Commercialization Agreement with InnoCare for Tafasitamab in Greater China
Planegg/Munich, Germany - August 17, 2021 - MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that Incyte, its development and commercialization partner for tafasitamab, entered into a collaboration and lic [ … ]
Wed, 28.07.2021
MorphoSys AG
Media Release
MorphoSys AG Reports Second Quarter and First Half 2021 Results
- Monjuvi U.S. net product sales of € 14.9 million (US$ 18.0 million), 16% growth Q-Q
- MorphoSys announced and subsequently completed its acquisition of Constellation Pharmaceuticals
- Announced and closed ~US$ 2.0 billion strategic funding partnership with Royalty Ph [ … ]
Mon, 26.07.2021
MorphoSys AG
Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No 596/2014
Planegg/Munich, Germany, July 26, 2021
Ad hoc: MorphoSys AG to update financial guidance for 2021 and reduce financial liabilities
MorphoSys AG (FSE: MOR; NASDAQ: MOR) announces today an update of its financial guidance for 2021 after prelim [ … ]
Wed, 21.07.2021
MorphoSys AG
Conference Call Alert
Planegg/Munich, Germany, July 21, 2021
Invitation to MorphoSys' Second Quarter and First Half 2021 Results Conference Call on July 29, 2021
MorphoSys AG (FSE:MOR; NASDAQ:MOR), a commercial-stage biopharmaceutical company and a leader in antibody and protein technologies, will publish its results for the second quarter and fi [ … ]
Fri, 16.07.2021
MorphoSys AG
Media Release
MorphoSys Concludes a US$ 100 Million Capital Increase to Implement the Purchase of 1,337,552 shares by Royalty Pharma
MorphoSys AG (FSE: MOR; NASDAQ: MOR) ("MorphoSys") today announced that its Management Board, with the approval of the Supervisory Board, has passed a resolution to increase the share capital of MorphoSys AG by issu [ … ]
Thu, 15.07.2021
MorphoSys AG
Media Release
Planegg/Munich, Germany, July 15, 2021
MorphoSys to Complete Transformational Acquisition of Constellation Pharmaceuticals, Bolstering Its Position in Hematology-Oncology
Company Announces Successful Completion of Tender OfferMoves Forward with Strategic Funding Partnership with Royalty Pharma
MorphoSys AG (FSE: MOR; NASDAQ: MOR [ … ]
Thu, 01.07.2021
MorphoSys AG
Media ReleaseMorphoSys Announces Expiration of the Hart-Scott-Rodino Waiting Period for Acquisition of Constellation Pharmaceuticals
MorphoSys AG (FSE: MOR; NASDAQ: MOR) ("MorphoSys") today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), for its tender offer for Cons [ … ]